Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.
Brief Summary: This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.


Options:
A: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
B: Arm Label: albiglutide; Type: EXPERIMENTAL; Interventions: Biological: albiglutide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Arm Label: albiglutide up-titration; Type: EXPERIMENTAL; Interventions: Biological: albiglutide uptitration | Intervention Type: BIOLOGICAL; Name: albiglutide; Assigned to Arm(s): albiglutide | Intervention Type: BIOLOGICAL; Name: albiglutide uptitration; Assigned to Arm(s): albiglutide up-titration | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Placebo/Sitagliptin; Type: OTHER; Interventions: Drug: Placebo, Drug: Sitagliptin, Drug: Metformin, Drug: Pioglitazone | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Pioglitazone | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo/Sitagliptin | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo/Sitagliptin
D: Arm Label: Lira 0.6 + Met; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo, Drug: metformin | Arm Label: Lira 1.2 + Met; Type: EXPERIMENTAL; Interventions: Drug: placebo, Drug: liraglutide, Drug: metformin | Arm Label: Lira 1.8 + Met; Type: EXPERIMENTAL; Interventions: Drug: placebo, Drug: liraglutide, Drug: metformin | Arm Label: Glim + Met; Type: EXPERIMENTAL; Interventions: Drug: glimepiride, Drug: metformin, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 0.6 + Met | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 + Met | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glim + Met | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Glim + Met, Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glim + Met

Answer: A